Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.53
-0.8%
$12.66
$5.22
$27.38
$157.73M0.43146,626 shs93,634 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.68
-3.6%
$3.89
$3.36
$12.22
$157.06M1.1115,419 shs285 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.70
+4.1%
$0.84
$0.49
$4.28
$32.80M0.111.17 million shs409,168 shs
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
$1.54
-1.9%
$1.57
$0.77
$2.12
$153.66M2.251.58 million shs3.17 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
-0.79%+0.80%-1.57%-18.95%+87.29%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-1.84%-4.91%-7.05%-6.34%-53.76%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+4.12%-3.37%-29.11%-32.52%-48.77%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-1.91%-7.23%-9.41%+28.33%+45.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.9597 of 5 stars
3.50.01.72.72.61.71.3
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.851 of 5 stars
3.85.00.00.00.00.00.6
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.1659 of 5 stars
3.61.00.00.00.63.30.6
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
0.5545 of 5 stars
0.01.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50143.42% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00226.00% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.29
Buy$9.001,182.42% Upside
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RVPH, LFVN, MOLN, and SLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
4/24/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/1/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.21$2.05 per share6.11
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M26.31N/AN/A$3.99 per share0.92
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
$1M153.66N/AN/A$0.13 per share11.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.16N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/A-1,043.01%-42.20%-38.12%8/25/2025 (Estimated)
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.79N/AN/AN/AN/AN/A-302.31%8/13/2025 (Estimated)
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)

Latest RVPH, LFVN, MOLN, and SLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/15/2025Q1 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.21-$0.13+$0.08-$0.13N/AN/A
5/13/2025Q1 2025
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/31/2025Q4 2024
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.22-$0.15+$0.07-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.44%N/A26.09%3 Years
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
N/AN/AN/AN/AN/A

Latest RVPH, LFVN, MOLN, and SLS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.54
0.54
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
17.38%

Insider Ownership

CompanyInsider Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
546.74 million34.04 millionOptionable
Galena Biopharma, Inc. stock logo
SLS
Galena Biopharma
1099.78 million98.38 millionNot Optionable

Recent News About These Companies

Sellas Life Sciences: Tons Of Completed Studies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.53 -0.10 (-0.79%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$12.52 0.00 (-0.04%)
As of 06/20/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.68 -0.14 (-3.64%)
Closing price 06/20/2025 02:48 PM Eastern
Extended Trading
$4.11 +0.43 (+11.63%)
As of 06/20/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.70 +0.03 (+4.12%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$0.68 -0.02 (-2.39%)
As of 06/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Galena Biopharma stock logo

Galena Biopharma NASDAQ:SLS

$1.54 -0.03 (-1.91%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.54 +0.00 (+0.06%)
As of 06/20/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.